Skip to main content
Top
Published in: Annals of Surgical Oncology 12/2021

01-11-2021 | Hepatocellular Carcinoma | Hepatobiliary Tumors

Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma

Authors: Tao Wei, MD, PhD, Xu-Feng Zhang, MD, PhD, Feng Xue, MD, MPH, Fabio Bagante, MD, Francesca Ratti, MD, Hugo P. Marques, MD, Silvia Silva, MD, Olivier Soubrane, MD, Vincent Lam, MD, George A. Poultsides, MD, Irinel Popescu, MD, Razvan Grigorie, MD, PhD, Sorin Alexandrescu, MD, Guillaume Martel, MD, Aklile Workneh, MD, Alfredo Guglielmi, MD, Tom Hugh, MD, Luca Aldrighetti, MD, Itaru Endo, MD, PhD, Timothy M. Pawlik, MD, MPH, PhD

Published in: Annals of Surgical Oncology | Issue 12/2021

Login to get access

Abstract

Backgrounds

Extrahepatic recurrence of hepatocellular carcinoma (HCC) after surgical resection is associated with unfavorable prognosis. The objectives of the current study were to identify the risk factors and develop a nomogram for the prediction of extrahepatic recurrence after initial curative surgery.

Methods

A total of 635 patients who underwent curative-intent resection for HCC between 2000 and 2017 were identified from an international multi-institutional database. The clinicopathological characteristics, risk factors, and long-term survival of patients with extrahepatic recurrence were analyzed. A nomogram for the prediction of extrahepatic recurrence was established and validated in 144 patients from an external cohort.

Results

Among the 635 patients in the derivative cohort, 283 (44.6%) experienced recurrence. Among patients who recurred, 80 (28.3%) patients had extrahepatic ± intrahepatic recurrence, whereas 203 (71.7%) had intrahepatic recurrence only. Extrahepatic recurrence was associated with more advanced initial tumor characteristics, early recurrence, and worse prognosis versus non-extrahepatic recurrence. A nomogram for the prediction of extrahepatic recurrence was developed using the β-coefficients from the identified risk factors, including neutrophil-to-lymphocyte ratio, multiple lesions, tumor size, and microvascular invasion. The nomogram demonstrated good ability to predict extrahepatic recurrence (c-index: training cohort 0.786; validation cohort: 0.845). The calibration plots demonstrated good agreement between estimated and observed extrahepatic recurrence (p = 0.658).

Conclusions

An externally validated nomogram was developed with good accuracy to predict extrahepatic recurrence following curative-intent resection of HCC. This nomogram may help identify patients at high risk of extrahepatic recurrence and guide surveillance protocols as well as adjuvant treatments.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
2.
go back to reference Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.CrossRef Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.CrossRef
3.
go back to reference Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–62.CrossRef Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–62.CrossRef
4.
go back to reference Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular Carcinoma: A multicenter study from China. JAMA Surg. 2019;154(3):209–17.CrossRef Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular Carcinoma: A multicenter study from China. JAMA Surg. 2019;154(3):209–17.CrossRef
5.
go back to reference Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Annals Surg. 2015;261(5):947–55.CrossRef Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Annals Surg. 2015;261(5):947–55.CrossRef
6.
go back to reference Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134(7):1908–16.CrossRef Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134(7):1908–16.CrossRef
7.
go back to reference Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–7.CrossRef Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–7.CrossRef
8.
go back to reference Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007;141(2):196–202.CrossRef Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007;141(2):196–202.CrossRef
9.
go back to reference Ochiai T, Ikoma H, Okamoto K, Kokuba Y, Sonoyama T, Otsuji E. Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection. World journal of surgery. 2012;36(1):136–43.CrossRef Ochiai T, Ikoma H, Okamoto K, Kokuba Y, Sonoyama T, Otsuji E. Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection. World journal of surgery. 2012;36(1):136–43.CrossRef
10.
go back to reference Mizuguchi S, Nishiyama N, Izumi N, et al. Clinical Significance of Multiple Pulmonary Metastasectomy for Hepatocellular Carcinoma. World J Surg. 2016;40(2):380–7.CrossRef Mizuguchi S, Nishiyama N, Izumi N, et al. Clinical Significance of Multiple Pulmonary Metastasectomy for Hepatocellular Carcinoma. World J Surg. 2016;40(2):380–7.CrossRef
11.
go back to reference Han B, Li C, Meng H, et al. Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population. Biosci Trends. 2019;13(1):10–22.CrossRef Han B, Li C, Meng H, et al. Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population. Biosci Trends. 2019;13(1):10–22.CrossRef
12.
go back to reference Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol. 2019;25(7):789–807.CrossRef Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol. 2019;25(7):789–807.CrossRef
13.
go back to reference Shinkawa H, Tanaka S, Takemura S, et al. Nomograms predicting extra- and early intrahepatic recurrence after hepatic resection of hepatocellular carcinoma. Surgery. 2021;169(4):922–8.CrossRef Shinkawa H, Tanaka S, Takemura S, et al. Nomograms predicting extra- and early intrahepatic recurrence after hepatic resection of hepatocellular carcinoma. Surgery. 2021;169(4):922–8.CrossRef
14.
go back to reference Wei T, Zhang XF, Bagante F, et al. Tumor necrosis impacts prognosis of patients undergoing curative-intent hepatocellular carcinoma. Ann Surg Oncol. 2021;28(2):797–805.CrossRef Wei T, Zhang XF, Bagante F, et al. Tumor necrosis impacts prognosis of patients undergoing curative-intent hepatocellular carcinoma. Ann Surg Oncol. 2021;28(2):797–805.CrossRef
15.
go back to reference Nault JC, De Reynies A, Villanueva A, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145(1):176–87.CrossRef Nault JC, De Reynies A, Villanueva A, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145(1):176–87.CrossRef
16.
go back to reference Tsilimigras DI, Bagante F, Sahara K, et al. Prognosis after resection of Barcelona Clinic Liver Cancer (BCLC) stage 0, A, and B hepatocellular carcinoma: A comprehensive assessment of the current BCLC classification. Annals Surg Oncol. 2019;26(11):3693–700.CrossRef Tsilimigras DI, Bagante F, Sahara K, et al. Prognosis after resection of Barcelona Clinic Liver Cancer (BCLC) stage 0, A, and B hepatocellular carcinoma: A comprehensive assessment of the current BCLC classification. Annals Surg Oncol. 2019;26(11):3693–700.CrossRef
17.
go back to reference Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Annals Surg. 2006;243(2):229–35.CrossRef Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Annals Surg. 2006;243(2):229–35.CrossRef
18.
go back to reference Akateh C, Black SM, Conteh L, et al. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol. 2019;25(28):3704–21.CrossRef Akateh C, Black SM, Conteh L, et al. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol. 2019;25(28):3704–21.CrossRef
19.
go back to reference Taketomi A, Toshima T, Kitagawa D, et al. Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Annals Surg Oncol. 2010;17(10):2740–6.CrossRef Taketomi A, Toshima T, Kitagawa D, et al. Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Annals Surg Oncol. 2010;17(10):2740–6.CrossRef
20.
go back to reference Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transplant. 2005;11(9):1086–92.CrossRef Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transplant. 2005;11(9):1086–92.CrossRef
21.
go back to reference Zhang Q, Rong Y, Yi K, Huang L, Chen M, Wang F. Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications. Theranostics. 2020;10(26):12060–71.CrossRef Zhang Q, Rong Y, Yi K, Huang L, Chen M, Wang F. Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications. Theranostics. 2020;10(26):12060–71.CrossRef
22.
go back to reference Hirokawa F, Hayashi M, Miyamoto Y, et al. Surgical treatment of extrahepatic recurrence of hepatocellular carcinoma. Langenbeck’s Arch Surg. 2014;399(8):1057–64.CrossRef Hirokawa F, Hayashi M, Miyamoto Y, et al. Surgical treatment of extrahepatic recurrence of hepatocellular carcinoma. Langenbeck’s Arch Surg. 2014;399(8):1057–64.CrossRef
23.
go back to reference Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Annal Surg. 2009;249(5):799–805.CrossRef Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Annal Surg. 2009;249(5):799–805.CrossRef
24.
go back to reference Ha SY, Choi S, Park S, et al. Prognostic effect of preoperative neutrophil-lymphocyte ratio is related with tumor necrosis and tumor-infiltrating lymphocytes in hepatocellular carcinoma. Virchows Archiv. 2020;47(6):807–16.CrossRef Ha SY, Choi S, Park S, et al. Prognostic effect of preoperative neutrophil-lymphocyte ratio is related with tumor necrosis and tumor-infiltrating lymphocytes in hepatocellular carcinoma. Virchows Archiv. 2020;47(6):807–16.CrossRef
25.
go back to reference Mano Y, Shirabe K, Yamashita Y, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Annals Surg. 2013;258(2):301–5.CrossRef Mano Y, Shirabe K, Yamashita Y, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Annals Surg. 2013;258(2):301–5.CrossRef
26.
go back to reference Wan S, Kuo N, Kryczek I, Zou W, Welling TH. Myeloid cells in hepatocellular carcinoma. Hepatology. 2015;62(4):1304–12.CrossRef Wan S, Kuo N, Kryczek I, Zou W, Welling TH. Myeloid cells in hepatocellular carcinoma. Hepatology. 2015;62(4):1304–12.CrossRef
27.
go back to reference Bagante F, Tran TB, Postlewait LM, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. J Surg Oncol. 2015;112(2):164–72.CrossRef Bagante F, Tran TB, Postlewait LM, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. J Surg Oncol. 2015;112(2):164–72.CrossRef
28.
go back to reference Spolverato G, Maqsood H, Kim Y, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreatico-biliary malignancies. J Surg Oncol. 2015;111(7):868–74.CrossRef Spolverato G, Maqsood H, Kim Y, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreatico-biliary malignancies. J Surg Oncol. 2015;111(7):868–74.CrossRef
29.
go back to reference Sasaki K, Shindoh J, Margonis GA, et al. Effect of background liver cirrhosis on outcomes of hepatectomy for hepatocellular carcinoma. JAMA Surg. 2017;152(3):e165059.CrossRef Sasaki K, Shindoh J, Margonis GA, et al. Effect of background liver cirrhosis on outcomes of hepatectomy for hepatocellular carcinoma. JAMA Surg. 2017;152(3):e165059.CrossRef
30.
go back to reference Utsunomiya T, Shimada M, Morine Y, Tajima A, Imoto I. Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis. Cancer Sci. 2014;105(7):749–54.CrossRef Utsunomiya T, Shimada M, Morine Y, Tajima A, Imoto I. Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis. Cancer Sci. 2014;105(7):749–54.CrossRef
31.
go back to reference Kim Y, Spolverato G, Ejaz A, et al. A nomogram to predict overall survival and disease-free survival after curative resection of gastric adenocarcinoma. Annals Surg Oncol. 2015;22(6):1828–35.CrossRef Kim Y, Spolverato G, Ejaz A, et al. A nomogram to predict overall survival and disease-free survival after curative resection of gastric adenocarcinoma. Annals Surg Oncol. 2015;22(6):1828–35.CrossRef
32.
go back to reference Bagante F, Spolverato G, Ruzzenente A, et al. Validation of a nomogram to predict the risk of perioperative blood transfusion for liver resection. World J Surg. 2016;40(10):2481–9.CrossRef Bagante F, Spolverato G, Ruzzenente A, et al. Validation of a nomogram to predict the risk of perioperative blood transfusion for liver resection. World J Surg. 2016;40(10):2481–9.CrossRef
33.
go back to reference Bischof DA, Kim Y, Behman R, et al. A nomogram to predict disease-free survival after surgical resection of GIST. J Gastrointest Surg. 2014;18(12):2123–9.CrossRef Bischof DA, Kim Y, Behman R, et al. A nomogram to predict disease-free survival after surgical resection of GIST. J Gastrointest Surg. 2014;18(12):2123–9.CrossRef
34.
go back to reference Yoon YS, Kim HK, Kim J, et al. Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol. 2010;17(10):2795–801.CrossRef Yoon YS, Kim HK, Kim J, et al. Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol. 2010;17(10):2795–801.CrossRef
35.
go back to reference Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–54.CrossRef Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–54.CrossRef
36.
go back to reference Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study. Hepatol Res. 2014;44(5):523–31.CrossRef Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study. Hepatol Res. 2014;44(5):523–31.CrossRef
37.
go back to reference Liao Y, Zheng Y, He W, et al. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncol Lett. 2017;13(2):984–92.CrossRef Liao Y, Zheng Y, He W, et al. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncol Lett. 2017;13(2):984–92.CrossRef
38.
go back to reference Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Disease Primers. 2021;7(1):6.CrossRef Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Disease Primers. 2021;7(1):6.CrossRef
39.
go back to reference Spolverato G, Ejaz A, Kim Y, et al. Readmission incidence and associated factors after a hepatic resection at a major hepato-pancreatico-biliary academic centre. HPB (Oxford). 2014;16(11):972–8.CrossRef Spolverato G, Ejaz A, Kim Y, et al. Readmission incidence and associated factors after a hepatic resection at a major hepato-pancreatico-biliary academic centre. HPB (Oxford). 2014;16(11):972–8.CrossRef
Metadata
Title
Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma
Authors
Tao Wei, MD, PhD
Xu-Feng Zhang, MD, PhD
Feng Xue, MD, MPH
Fabio Bagante, MD
Francesca Ratti, MD
Hugo P. Marques, MD
Silvia Silva, MD
Olivier Soubrane, MD
Vincent Lam, MD
George A. Poultsides, MD
Irinel Popescu, MD
Razvan Grigorie, MD, PhD
Sorin Alexandrescu, MD
Guillaume Martel, MD
Aklile Workneh, MD
Alfredo Guglielmi, MD
Tom Hugh, MD
Luca Aldrighetti, MD
Itaru Endo, MD, PhD
Timothy M. Pawlik, MD, MPH, PhD
Publication date
01-11-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 12/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-10142-7

Other articles of this Issue 12/2021

Annals of Surgical Oncology 12/2021 Go to the issue